Lisa is Executive Vice President and Chief Medical Officer of Editas Medicine. She joined Editas Medicine in November 2020 and is responsible for leading the development activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic indications including, ophthalmology, oncology, hematology, and immunologic diseases.

Lisa brings to Editas more than 25 years of experience in clinical research and drug development in both industry and academia. Lisa joined Editas Medicine from Bayer Pharmaceuticals where she spent more than 10 years in drug development, leading teams from early research and drug discovery through regulatory approval, commercial launch, and life cycle management. Most recently, she served as head of Bayer’s Rare Diseases, Cell & Gene Therapy therapeutic area.

Earlier in her career, Lisa spent more than 15 years at the Robert Wood Johnson Medical School at Rutgers University in academic practice working in areas including benign and malignant hematology, solid tumors, bone marrow failure syndromes, thrombosis and hemostasis, and immunologic disorders, including cytopenias and immune deficiencies.

Lisa received her M.D. at the University of Virginia, Charlottesville during which she received additional training in translational research in autoimmune disease, immune deficiencies, and disorders of complement, at the National Institute for Allergy and Infectious Disease in Washington, DC, and completed a preceptorship in pediatric cardiovascular care at Mayo Clinic, in Rochester, Minnesota. Lisa completed her residency and qualification in pediatrics at Duke University and post-graduate fellowship and qualification in hematology and oncology at the Children’s Hospital of Philadelphia.